Display options
Cite
Lynch GW, Selleck P, Sullivan JS. Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza. J Mol Genet Med. 2009;3(2):205-9doi: 10.4172/1747-0862.1000036.
Lynch, G. W., Selleck, P., & Sullivan, J. S. (2009). Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza. Journal of molecular and genetic medicine : an international journal of biomedical research, 3(2), 205-9. https://doi.org/10.4172/1747-0862.1000036
Lynch, Garry W, et al. "Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza." Journal of molecular and genetic medicine : an international journal of biomedical research vol. 3,2 (2009): 205-9. doi: https://doi.org/10.4172/1747-0862.1000036
Lynch GW, Selleck P, Sullivan JS. Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza. J Mol Genet Med. 2009 Dec 15;3(2):205-9. doi: 10.4172/1747-0862.1000036. PMID: 20076792; PMCID: PMC2805841.
Copy Download .nbib Format: NLM
Share it on

J Mol Genet Med. 2009 Dec 15;3(2):205-9. doi: 10.4172/1747-0862.1000036.

Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza.

Journal of molecular and genetic medicine : an international journal of biomedical research

Garry W Lynch, Paul Selleck, John S Sullivan

PMID: 20076792 PMCID: PMC2805841 DOI: 10.4172/1747-0862.1000036

Abstract

Well understood are the adaptive and dramatic neutralizing homosubtypic antibody responses to hypervariable, immunodominant sites of the hemagglutinin (HA) and neuraminidase (NA) of individual influenza strains. These define influenza subtypes and vaccines modelled upon their HA and NA antigens provide seasonal neutralizing antibody protection against subsequent exposure to the strain and its close relatives, but give little if any protection against antigenically drifted or shifted strains. Contrasting to this is a different form of acquired antibody response, called heterosubtypic immunity. This provides a more seasoned adaptive antibody response to immune-recessive epitopes that are highly-conserved amongst strains. Although, such responses are of lower individual amplitudes than seasonal mechanisms they are active across influenza subtypes, and may give pre-emptive protection against new strains yet to emerge. Heterosubtypic immunities have been well studied in animals, but surprisingly there is minimal evidence for this type of antibody immunity in humans. Thus championed is the notion that seasoned humoral responses can through repeated exposure to sites widely conserved across different strains, cumulatively provide humans with a level of broad protection against emergent novel strains, such as H5N1, that is not afforded by seasonal humoral responses.

Keywords: H1N1; H5N1; Influenza; antibody; heterosubtypic; immunity; pandemic

References

  1. Nature. 2008 May 29;453(7195):667-71 - PubMed
  2. PLoS Med. 2007 Feb;4(2):e59 - PubMed
  3. Expert Rev Anti Infect Ther. 2003 Dec;1(4):627-38 - PubMed
  4. Nature. 1977 Mar 3;266(5597):52-4 - PubMed
  5. J Virol. 2001 Jun;75(11):5141-50 - PubMed
  6. J Gen Virol. 1991 Jul;72 ( Pt 7):1699-702 - PubMed
  7. J Clin Invest. 2008 Oct;118(10):3478-90 - PubMed
  8. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):246-51 - PubMed
  9. J Virol. 1999 Jul;73(7):5637-45 - PubMed
  10. J Immunol. 1999 Jun 15;162(12):7578-83 - PubMed
  11. Annu Rev Microbiol. 1983;37:529-49 - PubMed
  12. PLoS Med. 2007 May;4(5):e178 - PubMed
  13. Vaccine. 2009 Nov 5;27(47):6512-21 - PubMed
  14. PLoS One. 2007 Nov 21;2(11):e1190 - PubMed
  15. Virol J. 2008 Nov 28;5:144 - PubMed
  16. Dev Biol (Basel). 2003;115:25-30 - PubMed
  17. Emerg Infect Dis. 2006 Jan;12(1):48-54 - PubMed
  18. Infect Immun. 1982 Jun;36(3):1102-8 - PubMed
  19. Microbes Infect. 2008 Jul;10(9):1024-9 - PubMed
  20. Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15987-91 - PubMed
  21. J Clin Invest. 2008 Oct;118(10):3273-5 - PubMed
  22. Science. 2009 Apr 10;324(5924):246-51 - PubMed
  23. Vaccine. 1986 Mar;4(1):50-4 - PubMed
  24. Vaccine. 2005 Nov 16;23(46-47):5404-10 - PubMed
  25. J Gen Virol. 1990 May;71 ( Pt 5):1169-79 - PubMed
  26. Emerg Infect Dis. 2007 Mar;13(3):510-2 - PubMed
  27. J Immunol. 1975 Aug;115(2):434-9 - PubMed
  28. Clin Infect Dis. 2001 Oct 15;33(8):1375-8 - PubMed
  29. J Infect Dis. 2007 Nov 1;196(9):1313-20 - PubMed
  30. Ann Intern Med. 2006 Oct 17;145(8):599-609 - PubMed
  31. J Infect Dis. 1978 Feb;137(2):194-6 - PubMed
  32. J Immunol. 2008 Feb 1;180(3):1758-68 - PubMed
  33. Nat Struct Mol Biol. 2009 Mar;16(3):265-73 - PubMed
  34. Emerg Infect Dis. 2006 Jan;12(1):15-22 - PubMed
  35. Emerg Infect Dis. 2008 Jan;14(1):121-8 - PubMed
  36. J Virol. 2008 Jun;82(11):5161-6 - PubMed
  37. J Gen Virol. 1996 Jul;77 ( Pt 7):1483-7 - PubMed
  38. Dev Biol Stand. 1975;28:253-72 - PubMed
  39. Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):5986-91 - PubMed
  40. J Clin Virol. 2008 Oct;43(2):241-3 - PubMed
  41. Trans Assoc Am Physicians. 1965;78:323-33 - PubMed
  42. Euro Surveill. 2009 Aug 06;14(31): - PubMed
  43. N Engl J Med. 2007 Oct 4;357(14):1450-1 - PubMed
  44. Immunity. 2006 Feb;24(2):121-4 - PubMed
  45. J Infect Dis. 2006 Jan 1;193(1):49-53 - PubMed
  46. Vaccine. 2007 Sep 28;25(39-40):6845-51 - PubMed
  47. J Biol Chem. 2008 Apr 25;283(17):11382-7 - PubMed
  48. J Immunol. 2008 Sep 15;181(6):4168-76 - PubMed
  49. Virol J. 2008 Mar 20;5:44 - PubMed

Publication Types